Open AccessDosing of Clopidogrel for Platelet Inhibition in Infants and Young Children
Author(s) -
Jennifer S. Li,
Eric Yow,
Katherine Berezny,
Paula M. Bokesch,
Matsato Takahashi,
T.P. Graham,
Stephen P. Sanders,
Daniel Sidi,
Damien Bonnet,
Peter Ewert,
Lisa K. Jennings,
Alan D. Michelson
Publication year - 2008
Publication title -
circulation
Language(s) - English
Resource type - Journals
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.107.715821
Subject(s) - medicine , clopidogrel , tolerability , aspirin , placebo , randomized controlled trial , anesthesia , pharmacodynamics , dosing , confidence interval , platelet , loading dose , cardiology , adverse effect , pharmacokinetics , pathology , alternative medicine
Infants and young children with certain types of heart disease are at increased risk for thromboses. Clopidogrel 75 mg/d is used in adults to prevent thrombotic events. The dose to achieve similar platelet inhibition in children is unknown. The objectives of the present study were (1) to determine the dose of clopidogrel needed in infants and young children to achieve a mean 30% to 50% inhibition of 5-micromol/L ADP-induced platelet aggregation (ie, inhibition similar to that observed with 75 mg in adults) and (2) to assess the safety and tolerability of clopidogrel in infants and young children.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom